135 related articles for article (PubMed ID: 35362266)
21. Role of cytoblock on pleural effusion for diagnosis of malignant disease.
Shahini L; Hoxha M; Marku F; Morina B; Cena V; Kabashi K; Mustafa L
Diagn Cytopathol; 2023 Nov; 51(11):684-688. PubMed ID: 37547992
[TBL] [Abstract][Full Text] [Related]
22. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
24. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
25. Cell origins and diagnostic accuracy of interleukin 27 in pleural effusions.
Yang WB; Liang QL; Ye ZJ; Niu CM; Ma WL; Xiong XZ; Du RH; Zhou Q; Zhang JC; Shi HZ
PLoS One; 2012; 7(7):e40450. PubMed ID: 22792330
[TBL] [Abstract][Full Text] [Related]
26. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions.
Han J; Cao S; Zhang K; Zhao G; Xin Y; Dong Q; Yan Y; Cui J
J Cardiothorac Surg; 2012 Nov; 7():121. PubMed ID: 23148562
[TBL] [Abstract][Full Text] [Related]
28. Morphological markers of chromosomal instability as predictors of malignancy in pleural effusion.
Aggarwal P; Handa U; Bhagat R; Aggarwal D
Diagn Cytopathol; 2024 Feb; 52(2):76-81. PubMed ID: 37946685
[TBL] [Abstract][Full Text] [Related]
29. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).
Verma A; Abisheganaden J; Light RW
Lung; 2016 Feb; 194(1):147-53. PubMed ID: 26678281
[TBL] [Abstract][Full Text] [Related]
30. [Role of c-c chemokines in the determination of pleural effusion etiology].
Trzaska-Sobczak M; Pierzchała W; Brozek G; Farnik M
Wiad Lek; 2008; 61(7-9):190-4. PubMed ID: 19172830
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of procalcitonin in pleural effusions.
Wang CY; Hsiao YC; Jerng JS; Ho CC; Lai CC; Yu CJ; Hsueh PR; Yang PC
Eur J Clin Microbiol Infect Dis; 2011 Mar; 30(3):313-8. PubMed ID: 20938702
[TBL] [Abstract][Full Text] [Related]
32. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) on Reporting Pericardial Effusion Cytology.
Rodriguez EF; Jones R; Gabrielson M; Santos D; Pastorello RG; Maleki Z
Acta Cytol; 2020; 64(5):477-485. PubMed ID: 32422631
[TBL] [Abstract][Full Text] [Related]
33. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of diagnostic accuracy in 3026 pleural biopsies and matched pleural effusion cytology with clinical correlation: A methodological issue.
Zhang WL; Fang X; Qiu JQ; Cui T
Cancer Med; 2023 Feb; 12(4):4363-4364. PubMed ID: 36533542
[TBL] [Abstract][Full Text] [Related]
36. The usefulness of pleural fluid presepsin, C-reactive protein, and procalcitonin in distinguishing different causes of pleural effusions.
Watanabe N; Ishii T; Kita N; Kanaji N; Nakamura H; Nanki N; Ueda Y; Tojo Y; Kadowaki N; Bandoh S
BMC Pulm Med; 2018 Nov; 18(1):176. PubMed ID: 30470216
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of soluble B7-H4 in malignant pleural effusion].
Xu CH; Yu LK
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(2):117-8. PubMed ID: 22490695
[TBL] [Abstract][Full Text] [Related]
38. Calprotectin: a novel biomarker for the diagnosis of pleural effusion.
Sánchez-Otero N; Blanco-Prieto S; Páez de la Cadena M; Vázquez-Iglesias L; Fernández-Villar A; Botana-Rial MI; Rodríguez-Berrocal FJ
Br J Cancer; 2012 Nov; 107(11):1876-82. PubMed ID: 23093228
[TBL] [Abstract][Full Text] [Related]
39. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
[TBL] [Abstract][Full Text] [Related]
40. [Thoracocentesis for the assessment of lung cancer with pleural effusion].
Martín Díaz E; Arnau Obrer A; Martorell Cebollada M; Cantó Armengod A
Arch Bronconeumol; 2002 Oct; 38(10):479-84. PubMed ID: 12372198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
